BioXcel Therapeutics (BTAI) Cash from Financing Activities (2017 - 2026)

BioXcel Therapeutics has reported Cash from Financing Activities for 10 years, with the latest figure at $2.7 million in Q2 2026.

• On a quarterly basis, Cash from Financing Activities rose 1884.67% year-over-year to $2.7 million in Q2 2026; TTM through Jun 2026 was $46.1 million, a 155.3% increase from a year earlier, with the FY2025 full-year figure at $56.5 million, up 54.17% from the prior year.
• Cash from Financing Activities was $2.7 million for Q2 2026 at BioXcel Therapeutics, up from $232000.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $37.5 million in Q3 2025, with the low at $50000.0 in Q4 2022.
• Average Cash from Financing Activities over 5 years is $10.2 million, with a median of $4.3 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2026: Cash from Financing Activities jumped 42221.13% in 2022, then tumbled 98.24% in 2026.
• Over 5 years, Cash from Financing Activities stood at $50000.0 in 2022, then soared by 4146.0% to $2.1 million in 2023, then soared by 101.41% to $4.3 million in 2024, then jumped by 32.06% to $5.6 million in 2025, then slumped by 51.85% to $2.7 million in 2026.
• The last three Cash from Financing Activities figures came in at $2.7 million (Q2 2026), $232000.0 (Q1 2026), and $5.6 million (Q4 2025), per Business Quant data.